Publications by authors named "Gary Wilkinson"

Claim this Profile
P
Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects.
Timothy A Yap, David S P Tan, Anastasios Stathis, Geoffrey I Shapiro, Satoru Iwasa, Gary Wilkinson

Cancer Discov· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Dose-Escalation Study of the First-in-Class PDE3A-SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A.
Kyriakos P Papadopoulos, Meredith McKean, Silvia Goldoni, Isabelle Genvresse, Marine F Garrido, Gary Wilkinson

Clin Cancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment.
Christian Zurth, Pirjo Nykänen, Gary Wilkinson, Päivi Taavitsainen, Annamari Vuorela

Clin Pharmacokinet· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
Timothy A Yap, David S P Tan, Angelika Terbuch, Reece Caldwell, Christina Guo, Gary Wilkinson

Cancer Discov· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
Michael Heuser, Neil Palmisiano, Ioannis Mantzaris, Alice Mims, Courtney DiNardo, Gary Wilkinson

Leukemia· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Christian Zurth, Mikko Koskinen, Robert Fricke, Olaf Prien, Timo Korjamo, Gary Wilkinson

Eur J Drug Metab Pharmacokinet· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.
Andreas Schneeweiss, Dagmar Hess, Markus Joerger, Andrea Varga, Stacy Moulder, Gary Wilkinson

Cancers (Basel)· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.
Sophie Postel-Vinay, Karin Herbschleb, Christophe Massard, Victoria Woodcock, Jean-Charles Soria, Gary Wilkinson

Eur J Cancer· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.
Kevin M Foote, J Willem M Nissink, Thomas McGuire, Paul Turner, Sylvie Guichard, Gary Wilkinson

J Med Chem· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent.
Gary P Wilkinson, James P Taylor, Steve Shnyder, Patricia Cooper, Phil W Howard

Invest New Drugs· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis